SEC Form 4 · accession 0001209191-16-110591

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Mar 23, 2016

Accepted (ET)

Mar 25, 2016 · 3:20 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Mar 23, 2016	M	5,130	$35.35	A	270,414	D
Common Stock^F2,F3	Mar 23, 2016	S	3,030	$80.64	D	267,384	D
Common Stock^F2,F4	Mar 23, 2016	S	900	$81.48	D	266,484	D
Common Stock^F2,F5	Mar 23, 2016	S	800	$82.77	D	265,684	D
Common Stock^F2,F6	Mar 23, 2016	S	200	$83.33	D	265,484	D
Common Stock^F2,F7	Mar 23, 2016	S	200	$84.54	D	265,284	D
Common Stock	holding	—	—		—	13,286	I	401(k)
Common Stock	holding	—	—		—	122,700	I	Common Stock held in trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F8	$35.35	Mar 23, 2016	M	5,130	D	—	Jul 19, 2016	Common Stock	5,130	76,960	D

F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
F2Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3Open market sales reported on this line occurred at a weighted average price of $80.64 (range $80.15 to $81.12).
F4Open market sales reported on this line occurred at a weighted average price of $81.48 (range $81.22 to $82.02).
F5Open market sales reported on this line occurred at a weighted average price of $82.77 (range $82.28 to $83.25).
F6Open market sales reported on this line occurred at a weighted average price of $83.33 (range $83.29 to $83.37).
F7Open market sales reported on this line occurred at a weighted average price of $84.54 (range $84.53 to $84.54).
F8Fully vested.